Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin

Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet